会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Alpha 1a adrenergic receptor antagonists
    • Alpha 1a肾上腺素能受体拮抗剂
    • US5977115A
    • 1999-11-02
    • US973624
    • 1997-12-04
    • Michael A. PataneMark G. BockRoger M. FreidingerRose Ann PonticelloRandall C. Newton
    • Michael A. PataneMark G. BockRoger M. FreidingerRose Ann PonticelloRandall C. Newton
    • A61K31/445A61P13/02A61P15/00C07D211/64C07D295/155A61K31/495C07D295/12
    • C07D295/155C07D211/64
    • This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as selective alpha-1a adrenergic receptor antagonists. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing orthostatic hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia are achieved.
    • PCT No.PCT / US96 / 09425 Sec。 371 1997年12月4日第 102(e)1997年12月4日PCT PCT 1996年6月6日PCT公布。 出版物WO96 / 40136 日期:1996年12月19日本发明涉及某些新型化合物及其衍生物,其合成及其作为选择性α-1a肾上腺素能受体拮抗剂的用途。 这些化合物的一个应用是治疗良性前列腺增生。 这些化合物在其能够松弛富含α1a受体亚型的平滑肌组织的能力方面具有选择性,而不会同时引起体位性低血压。 发现一个这样的组织围绕尿道衬里。 因此,本发明化合物的一个用途是通过允许较少的受阻尿流量来对患有良性前列腺增生的男性提供急性缓解。 通过与人5-α还原酶抑制化合物的组合提供本发明化合物的另一种用途,使得可以实现急性和慢性缓解来自良性前列腺增生的作用。
    • 2. 发明授权
    • Alpha-1a adrenergic receptor antagonists
    • α-1a肾上腺素受体拮抗剂
    • US5661163A
    • 1997-08-26
    • US488272
    • 1995-06-07
    • Michael A. PataneMark G. BockRoger M. FreidingerRose Ann Ponticello
    • Michael A. PataneMark G. BockRoger M. FreidingerRose Ann Ponticello
    • A61K31/445A61P13/02A61P15/00C07D211/64C07D295/155C07D211/36
    • C07D295/155C07D211/64
    • This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as selective alpha-1a adrenergic receptor antagonists. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing orthostatic hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia are achieved.
    • 本发明涉及某些新化合物及其衍生物,其合成及其作为选择性α-1a肾上腺素能受体拮抗剂的用途。 这些化合物的一个应用是治疗良性前列腺增生。 这些化合物在其能够松弛富含α1a受体亚型的平滑肌组织的能力方面具有选择性,而不会同时引起体位性低血压。 发现一个这样的组织围绕尿道衬里。 因此,本发明化合物的一个用途是通过允许较少的受阻尿流量来对患有良性前列腺增生的男性提供急性缓解。 通过与人5-α还原酶抑制化合物的组合提供本发明化合物的另一种用途,使得可以实现急性和慢性缓解来自良性前列腺增生的作用。
    • 3. 发明授权
    • Alpha 1a adrenergic receptor antagonists
    • Alpha 1a肾上腺素能受体拮抗剂
    • US6075038A
    • 2000-06-13
    • US973622
    • 1997-12-04
    • Michael A. PataneMark G. BockRoger M. Freidinger
    • Michael A. PataneMark G. BockRoger M. Freidinger
    • A61K31/445A61K31/58A61P11/00C07D211/60C07D417/06A61K31/4453C07D211/06C07D401/04
    • C07D417/06A61K31/58C07D211/60
    • This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as selective alpha-1a adrenergic receptor antagonists. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing orthostatic hypotension. One such tissue is found surrounding the urethral fining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia are achieved.
    • PCT No.PCT / US96 / 09363 Sec。 371 1997年12月4日第 102(e)日期1997年12月4日PCT提交1996年6月4日PCT公布。 公开号WO96 / 40135 日期:1996年12月19日本发明涉及某些新型化合物及其衍生物,其合成及其作为选择性α-1a肾上腺素能受体拮抗剂的用途。 这些化合物的一个应用是治疗良性前列腺增生。 这些化合物在其能够松弛富含α1a受体亚型的平滑肌组织的能力方面具有选择性,而不会同时引起体位性低血压。 发现一个这样的组织围绕尿道澄清。 因此,本发明化合物的一个用途是通过允许较少的受阻尿流量来对患有良性前列腺增生的男性提供急性缓解。 通过与人5-α还原酶抑制化合物的组合提供本发明化合物的另一种用途,使得可以实现急性和慢性缓解来自良性前列腺增生的作用。